Compare AbCellera Biologics Inc (ABCL) vs NRG Energy Inc (NRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs NRG Energy Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while NRG Energy Inc trades at $136.27 (market cap $29.12B). The key difference: NRG Energy Inc is far larger — about 12.4× AbCellera Biologics Inc's market cap, and NRG Energy Inc pays a 1.38% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NRG | |
|---|---|---|
Market Cap | $2.35B | $29.12B |
Sector | Health | Utilities |
52-Week High | $8.12 | $184.03 |
52-Week Low | $2.78 | $120.65 |
Enterprise Value | $1.99B | $52.95B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
NRG Energy trades at $138.01, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $30.71B revenue and $864M net income, though Q1 2026 earnings missed expectations. Valuation metrics show a high P/E ratio of 154.96 but attractive P/S of 0.87. Recent corporate actions include a $0.48 dividend payment in May 2026.
Outlook remains cautiously optimistic with 64% analyst buy ratings, though elevated debt levels and recent earnings miss pose risks. The stock offers value through reasonable sales multiples and dividend income, but investors should monitor execution on 2026 EBITDA guidance of $5.3-5.8B and manage exposure to energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
